Proteomics firm Cellzome said this week it has entered into a joint project with Pfizer to use its Episphere chemoproteomics platform to investigate epigenetic factors involved in stem cell regulation.

The company will work with Pfizer's Pain & Sensory Disorders and Regenerative Medicine unit on the project. Cellzome is also currently involved in an epigenetics collaboration with GlaxoSmithKline using the Episphere platform screen for epigenetic drug targets related to undisclosed immuno-inflammatory diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.